Voice your opinion on congressional bill HR6973-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Enhanced Access to Affordable Medicines Act of 2022

This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.

House committee actions Actions

Committee
Mar. 09 2022	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Mar. 08 2022	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Mar. 08 2022	Introduced in House Introduced in House

House bill HR6973-117

Enhanced Access to Affordable Medicines Act of 2022

Promote the cause!

Or use this QR code